Skip to main content

Diabetic Nephropathy Type 2 clinical trials at University of California Health

1 research study open to eligible people

Showing trials for
  • Atrasentan in Patients With Proteinuric Glomerular Diseases

    open to eligible people ages 18 years and up

    The AFFINITY Study is a phase 2, open-label, basket study to evaluate the efficacy and safety of atrasentan in patients with proteinuric glomerular disease who are at risk of progressive loss of renal function.

    at UCLA

Last updated: